Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder

Overview

The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major depressive disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Full Title of Study: “A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Major Depressive Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double
  • Study Primary Completion Date: December 2007

Interventions

  • Drug: Quetiapine

Clinical Trial Outcome Measures

Primary Measures

  • Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 9.
    • Time Frame: Baseline to Week 9
    • MADRS total score (0-60 units), where lower scores indicate less depressive symptoms, calculated as Week 9 value – baseline value.

Secondary Measures

  • Change From Baseline in Health-related Quality of Life, Enjoyment and Satisfaction (Q-LES-Q)
    • Time Frame: Baseline to Week 9
    • Q-LES-Q as percent of maximum (0 to 100%) calculated as Week 9 – baseline, where higher values indicate better quality of life.
  • Change From Baseline for Satisfaction With Medication From Quality of Life, Enjoyment, Satisfaction Questionaire (Q-LES-Q)
    • Time Frame: Baseline to Week 9
    • Item 15 the Quality of Life, Enjoyment Satisfaction Questionnaire (score 1 least -5 best) on Q-LES-Q, calculated as Week 9 value – baseline value
  • Change From Baseline in Anxiety Symptoms Measured by Hamilton Anxiety 14 Item Scale (HAM-A)
    • Time Frame: Baseline to Week 9
    • Change in HAM-A total score (total score 0-56), calculated as Week 9 value – baseline value, where lower scores indicate less anxiety.
  • Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index
    • Time Frame: Baseline to Week 9
    • The Pittsburgh Sleep Quality Index is an eighteen questionnaire scored with 7 sleep component scores each on a 0 to 3 scale, total score range from 0 to 21, worst value 21, best value 0
  • Change From Baseline in Suicidal Thoughts as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Item 10
    • Time Frame: Baseline to Week 9
    • The suicide item is a single item of the Montgomery-Asberg Depression Rating Scale with a range of values from 0 to 6, worst value 6, best value 0
  • Change From Baseline in Somatic Symptoms Cluster From the Hamilton Anxiety Scale (HAM-A)
    • Time Frame: Baseline to Week 9
    • The Somatic symptom Cluster of the Hamilton Anxiety Scale is a 7 item cluster associated with somatic symptoms *somatic muscular, somatic sensory, cardiovascular system, respiratory system, gastrointestinal system, genitourinary system, autonomic system) with a range of values from 0 to 28, worst value 28, best value 0
  • Tolerability as Measured by Adverse Event Withdrawals During Treatment
    • Time Frame: Baseline to Week 9

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female patients, 66 years or older, with a documented clinical diagnosis of MDD. Exclusion Criteria:

  • The presence of dementia or mental disorder other than MDD within 6 months of enrolment, – Uncontrolled hypertension, substance or alcohol abuse – A current diagnosis of cancer or a current or past diagnosis of stroke

Gender Eligibility: All

Minimum Age: 66 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Martin Brecher, Seroquel Medical Science Director, AstraZeneca Pharmaceuticals
  • Overall Official(s)
    • Catherine Datto, MD, Study Director, AstraZeneca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.